Peak plasma rivaroxaban levels in patients weighing 120  kg or greater

Direct oral anticoagulants (DOACs) have become the drug of choice, increasingly replacing traditional vitamin K antagonists (VKA) for stroke prevention in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE) due to their advantages of fixed dosing and no requirement for drug monitoring. Furthermore, their use is expanding into the ischemic heart disease population [1]. However, there is ongoing concern regarding their use in those weighing ≥120 kg or who have a body mass index (BMI) ≥ 40 due to limited representation of this patient group in the phase 3 DOAC trials [2,3].
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research